@Marckemil @drdavidpalma @MeredithGiulia1 We attempted to quantify these trade offs in a planning study @donna_murrell @drdavidpalma https://t.co/TvJDP71sIQ
@DrewMoghanaki @drdavidpalma @DrBezjakRO @JeffBradleyMD @b_fischervaluck @soumon_rudra @ATB_MD @SBRT_CR @PercyLeeMD @samsonpp Agree that to ban is heavy handed. This case however highlights that sbrt can be risky business when we are faced on whether to pr
@DrewMoghanaki An important Q is what to do in central/ ultra-central tumours when achieving optimal PTV/ ITV cover conflicts with conforming to OAR constraints? A challenging scenario faced increasingly now a days; osrt addressed here: https://t.co/TRhFaf
RT @JoaquinJCabrera: Dra Samper. Tratamiento de los tumores ultracentrales con #SBRT #LCSM #revisionesonco18 https://t.co/nPUVZIaE3l Prior…
Dra Samper. Tratamiento de los tumores ultracentrales con #SBRT #LCSM #revisionesonco18 https://t.co/nPUVZIaE3l Priorizar la protección de OAR y adaptar fraccionamiento y dosis total
RT @DrewMoghanaki: And now, just published, you can read more about SUNSET. 🇨🇦 #radonc https://t.co/BjYX209knw https://t.co/lTOcqNYM9K
RT @DrewMoghanaki: And now, just published, you can read more about SUNSET. 🇨🇦 #radonc https://t.co/BjYX209knw https://t.co/lTOcqNYM9K
RT @DrewMoghanaki: And now, just published, you can read more about SUNSET. 🇨🇦 #radonc https://t.co/BjYX209knw https://t.co/lTOcqNYM9K
RT @DrewMoghanaki: And now, just published, you can read more about SUNSET. 🇨🇦 #radonc https://t.co/BjYX209knw https://t.co/lTOcqNYM9K
RT @DrewMoghanaki: And now, just published, you can read more about SUNSET. 🇨🇦 #radonc https://t.co/BjYX209knw https://t.co/lTOcqNYM9K
RT @DrewMoghanaki: And now, just published, you can read more about SUNSET. 🇨🇦 #radonc https://t.co/BjYX209knw https://t.co/lTOcqNYM9K
And now, just published, you can read more about SUNSET. 🇨🇦 #radonc https://t.co/BjYX209knw https://t.co/lTOcqNYM9K